Pembrolizumab for Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...
Publications
View AllTrastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
individualised decision making with an informed patient. Careful follow-up is then recommended. (using regimens active in
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- DE
- Publications
- 4
- Citations
- 6,746
External Links
Identifiers
- ROR
- https://ror.org/05hgh1g19